# Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

> **NCT04702490** · PHASE2 · UNKNOWN · sponsor: **Metacrine, Inc.** · enrollment: 120 (actual)

## Conditions studied

- NASH
- NASH - Nonalcoholic Steatohepatitis
- Type 2 Diabetes
- Diabetes Type 2
- Diabetes
- Fatty Liver
- Fatty Liver, Nonalcoholic
- NAFLD

## Interventions

- **DRUG:** MET409 Active
- **DRUG:** MET409 Placebo
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT04702490
- **Lead sponsor:** Metacrine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-15
- **Primary completion:** 2022-04
- **Final completion:** 2022-06
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04702490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04702490, "Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04702490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*